Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Takeda Acquires Biotech Firm ARIAD Pharmaceuticals

Friday, March 3, 2017   (0 Comments)
Posted by: Kate Oesterle
Share |

Takeda Pharmaceutical Company has completed the acquisition of biotechnology firm ARIAD Pharmaceuticals Inc., a move that it expects to strengthen and diversify its oncology business.

“The addition of ARIAD’s innovative targeted therapies and research and development capabilities strengthens and diversifies our oncology business, positioning Takeda for sustainable long-term growth in this priority therapeutic area,” said Christophe Weber, president and chief executive officer of Takeda.

A global, research and development-driven pharmaceutical company, Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda Oncology, its oncology business unit brand endeavors to deliver novel medicines to patients with cancer.

US-based ARIAD develops precision therapies for patients with rare cancers and utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.

Weber said the merger, both companies sees the global potential of brigatinib, an investigational drug product, which is expected to become a best-in-class ALK inhibitor for non-small cell lung cancer with the potential to achieve peak annual sales of over $1 billion. 

“This bodes very well for the future of our combined business, and we look forward to building on this strong start to maximize the benefit of Iclusig (ponatinib) and potential of brigatinib for cancer patients,” he said.

Read more.


Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal